{
  "id": 5351407,
  "title": "Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study",
  "url": "https://urgent.news/2026/09/03/ultragenyx-to-weigh-significant-cost-cuts-as-angelman-drug-fails-key",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T14:53:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/ultragenyx-angelman-syndrome-drug-results-cost-cuts/829528/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial",
        "url": "https://urgent.news/2026/09/02/stat-ultragenyx-drug-to-treat-angelman-syndrome-a-rare-disease-fails",
        "published": "2026-09-02T20:37:24.000Z"
      },
      {
        "outlet": "Endpoints News",
        "title": "Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for",
        "url": "https://urgent.news/2026/09/03/ultragenyxs-angelman-therapy-fails-phase-3-trial-in-setback-for",
        "published": "2026-09-03T01:35:17.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}